Jan 2026 $19 M Private placement after listing $10 to $50 million 194
CytoDyn Inc.: Private sale, Jan 2026 × Investors in this round 194 investors had bought by the notice of May 11, 2026: 194 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $19 M of $19 M offered
Smallest investment taken $15,000
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $2,275,050
Finders' fees none
Paid to its own people $1,616,900 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Jacob P. Lalezari · Executive Officer Robert E. Hoffman · Executive Officer Tyler E. Blok · Executive Officer Karen J. Brunke, Ph.D. · Director Lishomwa C. Ndhlovu, M.D., Ph.D. · Director Ryan M. Dunlap · Director Stephen M. Simes · Director Tanya D. Urbach · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Paulson Investment Company (CRD 5670) · New York, New York Sold in all US states Remarks in the notice On fees: “Excludes warrants to purchase Common Stock.”Signed by Tyler Blok, Chief Legal Officer. Source: SEC Form D, newest notice filed May 11, 2026. Read the notice at the SEC .
equity, options SEC Apr 2022 $22 M Private placement after listing $10 to $50 million 166
CytoDyn Inc.: Private sale, Apr 2022 × Investors in this round 166 investors had bought by the notice of Sep 19, 2022: 166 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $22 M of $22 M offered
Smallest investment taken $5,000
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Common Stock; Warrants to Purchase Common Stock; Common Stock issued upon exercise of Warrants Exemption claimed Rule 506(c): may be advertised publicly; every buyer must be a verified accredited investor
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $2,830,299
Finders' fees none
Paid to its own people $600,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Antonio Durkee Migliarese · Executive Officer Arvin Cyrus Arman · Executive Officer Nitya G. Ray · Executive Officer Scott A. Kelly · Executive Officer, Director Karen J. Brunke · Director Lishomwa C. Ndhlovu · Director Ryan G. Dunlap · Director Tanya Durkee Urbach · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Paulson Investment Company (CRD 5670) · New York, New York Sold in all US states Remarks in the notice On fees: “Excludes warrants to purchase Common Stock.”Signed by Antonio Migliarese, CFO & Interim President. Source: SEC Form D and 2 amendments, newest notice filed Sep 19, 2022. Read the notice at the SEC .
equity, options SEC Nov 2021 $11 M Private placement after listing $10 to $50 million 118
CytoDyn Inc.: Private sale, Nov 2021 × Investors in this round 118 investors had bought by the notice of Dec 3, 2021: 118 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $11 M of $54 M offered; $42 M still to sell
Smallest investment taken $10,000
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions $6,481,244
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Delaware People named in the notice Antonio Durkee Migliarese · Executive Officer Christopher G. Recknor · Executive Officer Nader Z. Pourhassan · Executive Officer, Director Nitya G. Ray · Executive Officer Scott A. Kelly · Executive Officer, Director Harish Z. Seethamraju · Director Jordan G. Naydenov · Director Lishomwa C. Ndhlovu · Director Tanya Durkee Urbach · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Paulson Investment Company (CRD 5670) · New York, New York Sold in AL, AZ, CA, CO, CT, FL, GA, IL, MD, MI, MN, MS, MT, NC, NJ, NV, NY, OK, OR, PA, SC, TN, TX, UT, VA, WA Remarks in the notice On fees: “Assumes maximum commissions earned. Excludes warrants to purchase Common Stock.”Signed by Antonio Migliarese, Chief Financial Officer. Source: SEC Form D, newest notice filed Dec 3, 2021. Read the notice at the SEC .
equity, options SEC Aug 2021 $3 M Private placement after listing $2 to $10 million 6
CytoDyn Inc.: Private sale, Aug 2021 × Investors in this round 6 investors had bought by the notice of Sep 16, 2021: 6 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $25 M offered; $22 M still to sell
Smallest investment taken $250,000
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Antonio G. Migliarese, C.P.A. · Executive Officer Christopher G. Recknor, M.D. · Executive Officer Nader Z. Pourhassan, Ph.D. · Executive Officer, Director Nitya G. Ray, Ph.D. · Executive Officer Scott A Kelly, M.D. · Executive Officer, Director Alan P. Timmins · Director Gordon A. Gardiner · Director Jordan G. Naydenov · Director Samir R. Patel, M.D. · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Antonio Migliarese, Cfo. Source: SEC Form D, newest notice filed Sep 16, 2021. Read the notice at the SEC .
equity SEC Nov 2020 $1 M Private placement after listing Under $2 million 1
CytoDyn Inc.: Private sale, Nov 2020 × Investors in this round 1 investor had bought by the notice of Dec 16, 2020: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $1 M of $1 M offered
Smallest investment taken $1,000,000
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Arian G. Colachis · Executive Officer Mahboob G. Rahman, M.D., Ph.D. · Executive Officer Michael D. Mulholland · Executive Officer Nader Z Pourhassan, Ph.D · Executive Officer, Director Nitya G. Ray, Ph.D. · Executive Officer Scott Kelly, M.D. · Executive Officer, Director Alan P. Timmins · Director Jordan G. Naydenov · Director Samir R. Patel, M.D. · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Arian Colachis, VP, Secretary and General Counsel. Source: SEC Form D, newest notice filed Dec 16, 2020. Read the notice at the SEC .
equity SEC Jan 2020 $8 M Private placement after listing $2 to $10 million 3
CytoDyn Inc.: Private sale, Jan 2020 × Investors in this round 3 investors had bought by the notice of Apr 7, 2020: 3 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $8 M of $11 M offered; $4 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Arian F Colachis · Executive Officer Craig Z Eastwood · Executive Officer Nader Z Pourhassan · Executive Officer, Director Alan P Timmins · Director David F Welch · Director Jordan G Naydenov · Director Scott A Kelly · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “Some of the proceeds may be used for general working capital purposes which may include the payment of salaries and other fees to those listed in Item 3.”Signed by Craig Eastwood, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed Apr 7, 2020. Read the notice at the SEC .
equity, options SEC Mar 2019 $8 M Private placement after listing $2 to $10 million 61
CytoDyn Inc.: Private sale, Mar 2019 × Investors in this round 61 investors had bought by the notice of Nov 12, 2019: 61 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $8 M of $20 M offered; $12 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Convertible Preferred Stock with Warrants Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $1,800,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions and payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Michael D. Mulholland · Executive Officer Nader Z. Pourhassan · Executive Officer, Director David F. Welch · Director Jordan G. Naydenov · Director Michael A. Klump · Director Scott A. Kelly · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Paulson Investment Company, LLC (CRD 5670) · Chicago, Illinois Sold in all US states Remarks in the notice On fees: “Assumes maximum fees earned.”On the use of proceeds: “Some of the proceeds may be used for general working capital purposes which may include the payment of salaries and other fees to those listed in Item 3.”Signed by Michael D. Mulholland, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed Nov 12, 2019. Read the notice at the SEC .
equity, options SEC Aug 2018 $13 M Private placement after listing $10 to $50 million 119
CytoDyn Inc.: Private sale, Aug 2018 × Investors in this round 119 investors had bought by the notice of Sep 10, 2018: 119 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $13 M of $25 M offered; $12 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $3,000,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions and payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Michael D. Mulholland · Executive Officer Nader Z. Pourhassan · Executive Officer, Director Anthony D. Caracciolo · Director Carl C. Dockery · Director Gregory A. Gould · Director Jordan G. Naydenov · Director Michael A. Klump · Director Scott A. Kelly · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Paulson Investment Company, LLC (CRD 5670) · Chicago, Illinois Sold in all US states Remarks in the notice On fees: “Assumes maximum commissions earned. Excludes value of warrants to purchase up to 5,000,000 shares of common stock.”On the use of proceeds: “Some of the proceeds may be used for general working capital purposes which may include the payment of salaries and other fees to those listed in Item 3.”Signed by Michael D. Mulholland, Chief Financial Officer. Source: SEC Form D, newest notice filed Sep 10, 2018. Read the notice at the SEC .
equity, options SEC Nov 2017 $18 M Private placement after listing $10 to $50 million 200
CytoDyn Inc.: Private sale, Nov 2017 × Investors in this round 200 investors had bought by the notice of Feb 28, 2018: 200 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $18 M of $18 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $1,714,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions and payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Anthony D. Caracciolo · Executive Officer, Director Michael D. Mulholland · Executive Officer Nader Z. Pourhassan · Executive Officer, Director Alan Bruce Montgomery · Director Carl C. Dockery · Director Denis R. Burger · Director Gregory A. Gould · Director Jordan G. Naydenov · Director Scott A. Kelly · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Paulson Investment Company, LLC (CRD 5670) · Chicago, Illinois Sold in all US states Remarks in the notice On fees: “Excludes value of warrants to purchase up to 2,813,490 shares of common stock.”On the use of proceeds: “Some of the proceeds may be used for general working capital purposes which may include the payment of salaries and other fees to those listed in Item 3.”Signed by Michael D. Mulholland, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed Feb 28, 2018. Read the notice at the SEC .
equity, options SEC May 2017 $1 M Private placement after listing Under $2 million 2
CytoDyn Inc.: Private sale, May 2017 × Investors in this round 2 investors had bought by the notice of Jun 14, 2017: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $1 M of $15 M offered; $14 M still to sell
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $1,266,500
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions and payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Anthony D. Caracciolo · Executive Officer, Director Michael D. Mulholland · Executive Officer Nadar Z. Pourhassan · Executive Officer, Director Alan Bruce Montgomery · Director Carl C. Dockery · Director Denis R. Burger · Director Gregory A. Gould · Director Jordan G. Naydenov · Director Scott A. Kelly · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Paulson Investment Company, LLC (CRD 5670) · Chicago, Illinois Sold in all US states Remarks in the notice On fees: “Assumes maximum commissions are earned. Excludes value of warrants to purchase shares of common stock.”On the use of proceeds: “Some of the proceeds may be used for general working capital purposes which may include the payment of salaries and other fees to those listed in Item 3.”Signed by Michael D. Mulholland, Chief Financial Officer. Source: SEC Form D, newest notice filed Jun 14, 2017. Read the notice at the SEC .
debt, options SEC Apr 2016 $4 M Private placement after listing $2 to $10 million 41
CytoDyn Inc.: Private sale, Apr 2016 × Investors in this round 41 investors had bought by the notice of May 11, 2016: 41 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $4 M of $10 M offered; $6 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $196,665
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Michael D. Mulholland · Executive Officer Nadar Z. Pourhassan · Executive Officer, Director Alan Bruce Montgomery · Director Anthony D. Caracciolo · Director Carl C. Dockery · Director Denis R. Burger · Director Gregory A. Gould · Director Jordan G. Naydenov · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Paulson Investment Company, LLC (CRD 5670) · Chicago, Illinois Sold in all US states Remarks in the notice On fees: “Placement Agent also received warrants to purchase up to 132,050 common shares.”On the use of proceeds: “Some of the proceeds may be used for general working capital purposes which may include the payment of salaries and other fees to those listed in Item 3.”Signed by Michael D. Mulholland, Chief Financial Officer, Treasurer and Secretary. Source: SEC Form D, newest notice filed May 11, 2016. Read the notice at the SEC .
equity, options SEC Sep 2015 $3 M Private placement after listing $2 to $10 million 67
CytoDyn Inc.: Private sale, Sep 2015 × Investors in this round 67 investors had bought by the notice of Oct 5, 2015: 67 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $4 M offered; $1 M still to sell
Smallest investment taken no minimum stated
What was sold equity, other: amended warrants Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $107,752
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions and payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Michael D. Mulholland · Executive Officer Nadar Z. Pourhassan · Executive Officer, Director Alan Bruce Montgomery · Director Anthony D. Caracciolo · Director Carl C. Dockery · Director Denis R. Burger · Director Gregory A. Gould · Director Jordan G. Naydenov · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Paulson Investment Company, LLC (CRD 5670) · Chicago, Illinois Sold in all US states Remarks in the notice On the amounts: “Conversion of indebtedness in exchange for common stock and amended warrants.”Signed by Michael D. Mulholland, Chief Financial Officer, Treasurer and Secretary. Source: SEC Form D, newest notice filed Oct 5, 2015. Read the notice at the SEC .
equity SEC Jun 2015 $33 M Private placement after listing $10 to $50 million 261
CytoDyn Inc.: Private sale, Jun 2015 × Investors in this round 261 investors had bought by the notice of Feb 23, 2016: 261 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $33 M of $33 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $3,598,460
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Michael D. Mulholland · Executive Officer Nadar Z. Pourhassan · Executive Officer, Director Alan Bruce Montgomery · Director Anthony D. Caracciolo · Director Carl C. Dockery · Director Denis R. Burger · Director Gregory A. Gould · Director Jordan G. Naydenov · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Paulson Investment Company, LLC (CRD 5670) · Chicago, Illinois Sold in all US states Remarks in the notice On fees: “Placement agent also received warrants to purchase up to 4,797,932 common shares.”On the use of proceeds: “Some of the proceeds may be used for general working capital purposes which may include the payment of salaries and other fees to those listed in Item 3.”Signed by Michael D. Mulholland, Chief Financial Officer, Treasurer and Secretary. Source: SEC Form D and 1 amendment, newest notice filed Feb 23, 2016. Read the notice at the SEC .
equity, options SEC Sep 2013 $15 M Private placement after listing $10 to $50 million 170
CytoDyn Inc.: Private sale, Sep 2013 × Investors in this round 170 investors had bought by the notice of Oct 29, 2013: 170 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $15 M of $15 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions $1,816,400
Finders' fees none
Paid to its own people $650,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions and payments to its own people as estimates
The company Corporation, incorporated in Colorado People named in the notice Michael Mulholland · Executive Officer Nadar Pourhassan · Executive Officer, Director Alan Bruce Montgomery · Director Anthony Caracciolo · Director Gregory Gould · Director Jordan Naydenov · Director Michael Nobel · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Paulson Investment Company, Inc. (CRD 5670) · Portland, Oregon Sold in AZ, CA, CO, CT, FL, GA, IA, IL, IN, LA, MA, MD, MI, MN, MS, NC, ND, NH, NJ, NM, NV, NY, OH, OK, OR, PA, SD, TX, UT, VA, WA, WI Remarks in the notice On fees: “Compensation to the placement agent also includes warrants to purchase appx 4,940,125 common shares. In addition, a 6% cash fee applies to exercises of investor warrants.”On the use of proceeds: “Represents compensation paid or payable to directors and executive officers in the ordinary course of business.”Signed by Michael D. Mulholland, Chief Financial Officer, Treasurer and Secretary. Source: SEC Form D and 1 amendment, newest notice filed Oct 29, 2013. Read the notice at the SEC .
equity, options SEC Oct 2012 $8 M No. 2 $2 to $10 million 34
CytoDyn Inc.: Raise no. 2, Oct 2012 × Investors in this round 34 investors had bought by the notice of Aug 5, 2013: 34 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $8 M of $10 M offered; $2 M still to sell
Smallest investment taken $25,000
What was sold equity, debt, options or other rights to buy securities, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions $120,000
Finders' fees none
Paid to its own people $750,000 (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Colorado People named in the notice Michael Mulholland · Executive Officer Nader Pourhassan · Executive Officer, Director Anthony Caracciolo · Director Gregory Gould · Director Jordan Naydenov · Director Michael Nobel · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Paulson Investment Company, Inc. (CRD 5670) · Portland, Oregon Sold in CA, CO, FL, MI, MN, NJ, NY, OR, SD, WA, WI Remarks in the notice On the use of proceeds: “Represents compensation paid or payable to directors and executive officers in the ordinary course of business.”Signed by Michael D. Mulholland, Chief Financial Officer, Treasurer and Secretary. Source: SEC Form D and 2 amendments, newest notice filed Aug 5, 2013. Read the notice at the SEC .
equity, debt, options SEC Dec 2011 $3 M No. 1 $2 to $10 million 86
CytoDyn Inc.: Raise no. 1, Dec 2011 × Investors in this round 86 investors had bought by the notice of Jan 17, 2012: 86 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $3 M offered
Smallest investment taken $1,500
What was sold equity
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Colorado People named in the notice Andrew T. Libby, Jr. · Executive Officer Kenneth J. Van Ness · Executive Officer, Director Anthony D. Caracciolo · Director George F. Dembow · Director George J. Gould, CPA · Director Jordan F. Naydenov · Director Ronald J. Tropp, Esq. · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “The offering has terminated and the remaining amount will not be sold.”Signed by Kenneth J. Van Ness, President, Chief Executive Officer, and Director. Source: SEC Form D, newest notice filed Jan 17, 2012. Read the notice at the SEC .
equity SEC